- Home
- ED vs VCEL Comparison
ED vs VCEL Comparison
Compare ED & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ED
- VCEL
- Stock Information
- Founded
- ED 1884
- VCEL 1989
- Country
- ED United States
- VCEL United States
- Employees
- ED N/A
- VCEL N/A
- Industry
- ED Power Generation
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ED Utilities
- VCEL Health Care
- Exchange
- ED Nasdaq
- VCEL Nasdaq
- Market Cap
- ED 36.4B
- VCEL 2.1B
- IPO Year
- ED N/A
- VCEL 1997
- Fundamental
- Price
- ED $99.70
- VCEL $42.55
- Analyst Decision
- ED Hold
- VCEL Strong Buy
- Analyst Count
- ED 10
- VCEL 8
- Target Price
- ED $104.90
- VCEL $62.00
- AVG Volume (30 Days)
- ED 2.8M
- VCEL 439.0K
- Earning Date
- ED 07-31-2025
- VCEL 07-31-2025
- Dividend Yield
- ED 3.39%
- VCEL N/A
- EPS Growth
- ED 4.34
- VCEL 521.85
- EPS
- ED 5.42
- VCEL 0.05
- Revenue
- ED $15,774,000,000.00
- VCEL $238,541,000.00
- Revenue This Year
- ED $8.61
- VCEL $23.03
- Revenue Next Year
- ED $4.15
- VCEL $24.52
- P/E Ratio
- ED $18.50
- VCEL $724.21
- Revenue Growth
- ED 8.49
- VCEL 14.80
- 52 Week Low
- ED $87.28
- VCEL $37.39
- 52 Week High
- ED $114.87
- VCEL $63.00
- Technical
- Relative Strength Index (RSI)
- ED 33.29
- VCEL 51.57
- Support Level
- ED $97.34
- VCEL $40.53
- Resistance Level
- ED $102.47
- VCEL $43.51
- Average True Range (ATR)
- ED 1.51
- VCEL 1.77
- MACD
- ED -0.26
- VCEL -0.08
- Stochastic Oscillator
- ED 11.84
- VCEL 42.62
About ED Consolidated Edison Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York - including New York City and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.